Findings

What do systematic reviews say?

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Myofunctional therapy vs continuous positive airway pressure (CPAP)

Snoring intensity: endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Myofunctional therapy vs respiratory exercises + nasal dilator strip

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Myofunctional therapy vs respiratory exercises + nasal dilator strip

Quality of sleep · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 97 participants
Moderate

Myofunctional therapy vs respiratory exercises + nasal dilator strip

AHI · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Low

Myofunctional therapy vs medical treatment

Daytime sleepiness (ESS): change from baseline. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Myofunctional therapy vs medical treatment

Quality of sleep · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Myofunctional therapy vs medical treatment

Snoring frequency: change from baseline. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Myofunctional therapy vs medical treatment

Snoring intensity: change from baseline. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 26 participants
Low

Myofunctional therapy vs waiting list control

Daytime sleepiness (ESS): change from baseline. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Myofunctional therapy vs waiting list control

Quality of sleep · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Myofunctional therapy vs waiting list control

AHI score change. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Low

Myofunctional therapy vs continuous positive airway pressure (CPAP)

Daytime sleepiness (ESS): endpoint score. · obstructive sleep apnoea

1 finding from 1 review

Myofunctional therapy (oropharyngeal exercises) for obstructive sleep apnoea 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 54 participants
Low

Surgery plus radiotherapy vs Chemotherapy (chemoradiotherapy)

Disease-free survival · Adults with oral cavity or oropharyngeal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
oral cavity
Disease-free survival: not reported (Iyer 2015).
0 studies
No studies found

Surgery plus radiotherapy vs Chemotherapy (chemoradiotherapy)

Total mortality · Adults with oral cavity or oropharyngeal cancer

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
oral cavity
Total mortality: study reported survival significantly better with surgery and RT vs chemoradiotherapy, but no useable data; 32 participants (1 RCT, Iyer 2015 oral cavity subgroup).
1 study · 32 participants
Very low

Surgery plus radiotherapy vs Chemotherapy (chemoradiotherapy)

Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
Adverse events: not reported for any participants (Iyer 2015).
0 studies
No studies found

Surgery plus radiotherapy vs Chemotherapy (chemoradiotherapy)

Recurrence · Adults with oral cavity or oropharyngeal cancer

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
oral cavity
Recurrence: not reported for the oral cancer subgroup (Iyer 2015).
0 studies
No studies found

Surgery plus radiotherapy vs Chemotherapy (chemoradiotherapy)

Locoregional recurrence · Adults with oral cavity or oropharyngeal cancer

1 finding from 1 review

Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment 2023 · Cochrane All outcomes
oral cavity
Locoregional recurrence: reported difference between groups not statistically significant (P=0.355), but no useable data; 32 participants (1 RCT, Iyer 2015).
1 study · 32 participants
Very low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Resolution or improvement of telangiectasias ( · people with telangiectasias and reticular veins

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 125 participants
Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.49 [0.09, 2.5]
2 studies · 125 participants
Low

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Adverse events ‐ matting ( · people with telangiectasias and reticular veins

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.31 [0.01, 7.53]
1 study · 99 participants
Low